Comparison of therapeutic effects of topical Isotretinoin %0.05 and Clindamycine %1 in the treatment of acne vulgaris

Comparison of therapeutic effects of topical Isotretinoin %0.05 with Clindamycine %1 in the treatment of papulo pustular acne vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105032581N2

Enrollment

Registered

2011-11-26

Start date

2011-08-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate acne vulgaris. Acne vulgaris

Interventions

Intervention 1: Group A: topical Isotretinon gel 0.05% every night on acne lesions for 3months. Intervention 2: Group B: 1% Clindamycine solution twice daily on acne lesion for 3months.

Treatment - Drugs

Group A: topical Isotretinon gel 0.05% every night on acne lesions for 3months

Group B: 1% Clindamycine solution twice daily on acne lesion for 3months

Eligibility

Sex/Gender

All

Age

11 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with mild to moderate acne between 11 to 30 years old; patients who have at most 20 inflammatory lesion (papule, pustule) in one side of face and don't have more than 3 nodule or cyst in the same side; tendency to intend in study. Exclusion criteria: pregnant and lactating women; patients who have used topical anti acne drugs in the recent month; patients who have used oral anti acne drugs in past 2 months; having any other facial skin disease other than acne; having sever nodulocystic acne; consumption of acne inducing drugs such as lithium, oral steroid, vit B12, brom and iodide drugs; patients who have more than 20 inflammatory lesion (papule, pustule) in one side of face and have more than 3 nodule or cyst in the same side.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity. Timepoint: every 30 days. Method of measurement: History and clinical examination.	—

Secondary

Measure	Time frame
Pustules. Timepoint: every 30 days. Method of measurement: clinical examination.;Total acne lesions. Timepoint: every 30 days. Method of measurement: clinical examination.;Index of acne severity. Timepoint: every 30 days. Method of measurement: clinical examination, statistical measurment.;Patient satisfaction. Timepoint: every 30 days. Method of measurement: Questionnare.;Comedones. Timepoint: every 30 days. Method of measurement: clinical examination.	—

Measure

Time frame

Pustules. Timepoint: every 30 days. Method of measurement: clinical examination.;Total acne lesions. Timepoint: every 30 days. Method of measurement: clinical examination.;Index of acne severity. Timepoint: every 30 days. Method of measurement: clinical examination, statistical measurment.;Patient satisfaction. Timepoint: every 30 days. Method of measurement: Questionnare.;Comedones. Timepoint: every 30 days. Method of measurement: clinical examination.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026